Literature DB >> 1849662

Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column.

J L Lear1, R K Kasliwal, A J Feyerabend, J P Pratt, P A Bunn, D G Dienhart, R Gonzalez, T K Johnson, D C Bloedow, S W Maddock.   

Abstract

Imaging of tumors by using radiolabeled monoclonal antibodies (MoAs) is hindered by the presence of background activity. To reduce this problem, the authors investigated the process of removing labeled MoAs from plasma at selected times by means of extracorporeal immunoadsorption. In seven patients with either lung or breast carcinoma, an indium-111-labeled murine antibody was intravenously administered. Six to 24 hours later, immunoadsorption was performed by passing the patients' plasma through a goat anti-mouse antibody column connected to a plasma separator. Whole-body computer images were obtained before and after the treatment. Blood pool activity in the images was reduced by an average of 59%, while tumor activity dropped by only 10%. Tumor-to-blood activity ratios therefore more than doubled, improving by an average of 121% between the pre- and posttreatment image sets. Eight of 12 areas of known disease and three areas of unknown but later documented disease were detected after the immunoadsorption process, while the three areas of unknown disease and three of the areas of known disease were not detected in the preclearance images. Thus, the feasibility of using extracorporeal immunoadsorption to improve MoA imaging of tumors was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849662     DOI: 10.1148/radiology.179.2.1849662

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  (124)I-huA33 antibody PET of colorectal cancer.

Authors:  Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

Review 2.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

Review 3.  Emerging trends for radioimmunotherapy in solid tumors.

Authors:  Maneesh Jain; Suprit Gupta; Sukhwinder Kaur; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Cancer Biother Radiopharm       Date:  2013-07-11       Impact factor: 3.099

4.  Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R G Melton; R H Begent
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

5.  Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.

Authors:  B Desrues; H Léna; F Brichory; M P Ramée; L Toujas; P Delaval; L Dazord
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.